PR Newswire·Aug 25, 2026, 9:02 AM ET

Shareholders who lost money in shares of acquired Aardvark Therapeutics, Inc. (NASDAQ: AARD) should contact Wolf Haldenstein Immediately

Wolf Haldenstein Adler Freeman & Herz LLP filed a securities class action lawsuit in the U.S. District Court for the Southern District of California against Aardvark Therapeutics, Inc. (NASDAQ: AARD).
The class period covers Aardvark securities purchased between February 13, 2025, and May 14, 2026, inclusive.
The lead plaintiff deadline for the case is set for October 13, 2026.
The complaint alleges that defendants failed to disclose that the drug candidate ARD-101 was less safe than represented, overstating its clinical, regulatory, & commercial prospects.
The truth regarding safety concerns emerged on February 27, 2026, when Aardvark voluntarily paused its Phase 3 HERO trial due to reversible cardiac observations in healthy volunteer studies.
Following the announcement, Aardvark's stock price fell $7.02 per share (56.2%) to close at $5.47 on March 2, 2026.
The lawsuit claims the company's public statements were materially false & misleading during the relevant times.
Investors may contact Gregory Stone, Director of Case & Financial Analysis, at (800) 575-0735 or (212) 545-4774 for no cost or obligation.